Suchergebnisse - "Xu, Xu Steven"

PubPharm (97)

41

A quick and accurate method for the estimation of covariate effects based on empirical Bayes estimates in mixed-effects modeling : Correction of bias due to shrinkage

enthalten in: Statistical methods in medical research | 2019

von Yuan, M. | Xu, X. | Yang, Y. | +6

42

Pharmacokinetics and Exposure-Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

enthalten in: Advances in therapy | 2018

von Xu, X. | Dimopoulos, M. | Sonneveld, P. | +13

43

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

enthalten in: Advances in therapy | 2018

von Xu, X. | Dimopoulos, M. | Sonneveld, P. | +13

44

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

enthalten in: Advances in therapy | 2018

von Xu, X. | Dimopoulos, M. | Sonneveld, P. | +13

45

Pharmacokinetics and Exposure–Response Analyses of Daratumumab in Combination Therapy Regimens for Patients with Multiple Myeloma

enthalten in: Advances in therapy | 2018

von Xu, X. | Dimopoulos, M. | Sonneveld, P. | +13

46

Full covariate modelling approach in population pharmacokinetics : understanding the underlying hypothesis tests and implications of multiplicity

enthalten in: British journal of clinical pharmacology | 2018

von Xu, X. | Yuan, M. | Zhu, H. | +6

47

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical pharmacokinetics | 2018

von Yan, X. | Clemens, P. | Puchalski, T. | +15

48

Influence of Disease and Patient Characteristics on Daratumumab Exposure and Clinical Outcomes in Relapsed or Refractory Multiple Myeloma

enthalten in: Clinical pharmacokinetics | 2018

von Yan, X. | Clemens, P. | Puchalski, T. | +15

49

Response to "The Role of FcRn in the Pharmacokinetics of Biologics in Patients with Multiple Myeloma"

enthalten in: Clinical pharmacology and therapeutics | 2017

von Xu, X. | Schecter, J. | Jansson, R. | +1

CommentOn: Clin Pharmacol Ther. 2017 Jun;101(6):721-724. - PMID 27859027

50

Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma

enthalten in: Blood advances | 2017

von Casneuf, T. | Xu, X. | Adams, H. | +11